Related Experiment Video
Updated: Jan 20, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized
Harutake Sawazaki1, Daiji Araki2, Yosuke Kitamura3
1Department of Urology, Tama-hokubu Medical Center, 1-7-1 Aobacho, Higashimurayama, Tokyo, 189-8511, Japan. harutake_sawazaki@tokyo-hmt.jp.
Purpose:
In a mouse model, degarelix generated the least metabolic consequences via low follicle-stimulating hormone (FSH) levels compared with orchiectomy and leuprolide after 4 months of androgen deprivation therapy (ADT). Here, we comparatively investigated the influence of ADT with degarelix or leuprolide on the development of metabolic syndrome in patients with prostate cancer (PCa).
Methods:
Patients with hormone-naive PCa were recruited. Eligible patients were randomized (1:1) to monthly degarelix or monthly leuprolide for 6 months. Key trial variables were monitored monthly. The primary endpoint was changes in fasting blood sugar (FBS). Secondary endpoints were changes in body weight, abdominal circumference, lipid profiles, and hemoglobin A1c (HbA1c) and FSH levels. Computed tomography was performed to measure subcutaneous and visceral fat areas before and after 6 months of ADT. Data were analyzed using the χ2 test, Student's t test, and analysis of variance.
Results:
From the 100 patients registered, 85 completed the trial (degarelix: 40 patients; leuprolide: 45 patients). Mean increases in FBS did not differ between the two arms. Similarly, there were no differences between the arms in mean increases in body weight, abdominal circumference, lipid profiles, HbA1c, or subcutaneous and visceral fat areas. Follicle-stimulating hormone levels were significantly lower in the degarelix arm than in the leuprolide arm (p < 0.05).
Conclusions:
Lipid and glucose metabolism did not differ significantly between the arms, while FSH levels were significantly lower in the degarelix arm.
Insights
Degarelix and leuprolide showed similar effects on metabolic syndrome development in prostate cancer patients. However, degarelix significantly reduced follicle-stimulating hormone (FSH) levels compared to leuprolide.
Area of Science:
- Endocrinology
- Metabolic Syndrome Research
- Prostate Cancer Therapeutics
Background:
- Androgen deprivation therapy (ADT) is a cornerstone in prostate cancer (PCa) treatment.
- Different ADT agents may have varying effects on metabolic health.
- Investigating metabolic consequences of ADT is crucial for patient well-being.
Purpose of the Study:
- To compare the effects of degarelix and leuprolide on metabolic syndrome development in hormone-naive PCa patients.
- To assess changes in fasting blood sugar, body weight, abdominal circumference, lipid profiles, HbA1c, and fat distribution.
- To evaluate differences in follicle-stimulating hormone (FSH) levels between the two treatment arms.
Main Methods:
- Randomized controlled trial comparing monthly degarelix versus monthly leuprolide for 6 months in 100 hormone-naive PCa patients.
- Primary endpoint: change in fasting blood sugar (FBS). Secondary endpoints included metabolic markers and FSH levels.
- Computed tomography (CT) assessed visceral and subcutaneous fat areas before and after treatment.
Main Results:
- No significant differences were observed in mean increases of FBS, body weight, abdominal circumference, lipid profiles, HbA1c, or fat areas between degarelix and leuprolide groups.
- Follicle-stimulating hormone (FSH) levels were significantly lower in the degarelix arm compared to the leuprolide arm (p < 0.05).
Conclusions:
- Degarelix and leuprolide demonstrate comparable efficacy in managing metabolic parameters during ADT for PCa.
- Degarelix achieves a more pronounced suppression of FSH levels compared to leuprolide.
- These findings suggest that while metabolic profiles are similar, hormonal effects differ between these ADT agents.
More Related Videos
Related Concept Videos
11:29miRNA Expression Analyses in Prostate Cancer Clinical Tissues
07:01Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
13:18How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
07:16Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
11:07Focal Laser Ablation of Prostate Cancer: An Office Procedure